help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DONNELLY, J. J.
Right arrow Articles by ULMER, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DONNELLY, J. J.
Right arrow Articles by ULMER, J. B.

Am. J. Respir. Crit. Care Med., Volume 162, Number 4, October 2000, S190-S193

Antigen Presentation and DNA Vaccines

JOHN J. DONNELLY, MARGARET A. LIU, and JEFFREY B. ULMER

Department of Vaccines and Gene Therapy Research, Chiron Corporation, Emeryville, California

There is reasonable evidence that both cross-priming and direct transfection of antigen-presenting cells (APCs) play a role in induction of immune responses by DNA vaccines. It is not known which mode is more important for priming cytotoxic T cell responses, but both are sufficient and neither alone is necessary. Hence, a rational strategy for increasing DNA vaccine potency would be to facilitate both pathways. With regard to cross-priming, a better understanding of the nature of the antigen transferred and the molecules/cells involved may suggest ways to design DNA vaccines to enhance this pathway. With respect to transfection of APCs, certain DNA formulations or delivery systems may be able to target APCs for increased DNA uptake. Other considerations include recruitment of APCs to the site of DNA injection and manipulation of these cells to ensure the proper activation state for priming immune responses. The burgeoning scientific literature in these areas indicates that much effort is currently being directed toward these goals.




This article has been cited by other articles:


Home page
 CVIHome page
R. W. Kaminski, K. R. Turbyfill, C. Chao, W. M. Ching, and E. V. Oaks
Mucosal Adjuvanticity of a Shigella Invasin Complex with DNA-Based Vaccines
Clin. Vaccine Immunol., April 1, 2009; 16(4): 574 - 586.
[Abstract] [Full Text] [PDF]

Home page
 Bioscience HorizonsHome page
N. Dunning
Leishmania vaccines: from leishmanization to the era of DNA technology
Bioscience Horizons, March 1, 2009; 2(1): 73 - 82.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
A. M. Talaat and K. Stemke-Hale
Expression Library Immunization: a Road Map for Discovery of Vaccines against Infectious Diseases
Infect. Immun., November 1, 2005; 73(11): 7089 - 7098.
[Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
I. K. Srivastava and M. A. Liu
Gene Vaccines
Ann Intern Med, April 1, 2003; 138(7): 550 - 559.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
D. Marsac, D. Loirat, C. Petit, O. Schwartz, and M.-L. Michel
Enhanced Presentation of Major Histocompatibility Complex Class I-Restricted Human Immunodeficiency Virus Type 1 (HIV-1) Gag-Specific Epitopes after DNA Immunization with Vectors Coding for Vesicular Stomatitis Virus Glycoprotein- Pseudotyped HIV-1 Gag Particles
J. Virol., August 1, 2002; 76(15): 7544 - 7553.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
M. F. Lipscomb and B. J. Masten
Dendritic Cells: Immune Regulators in Health and Disease
Physiol Rev, January 1, 2002; 82(1): 97 - 130.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. TOBIN
Asthma, Airway Biology, and Allergic Rhinitis in AJRCCM 2000
Am. J. Respir. Crit. Care Med., November 1, 2001; 164(9): 1559 - 1580.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2000 American Thoracic Society 		  Portfolio of grants